GSBC vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GSBC exhibits a stable financial profile with a Piotroski F-Score of 4/9, placing it in the 'Stable' health category. The stock is fundamentally undervalued, trading at $67.77, which is significantly below both its Graham Number ($89.49) and its growth-based Intrinsic Value ($182.61). However, this value is offset by stagnant revenue growth (1.00% YoY) and a strongly bearish insider sentiment with $1.28M in recent sales. While the company has a stellar track record of earnings beats, the current technical trend and insider activity suggest a lack of immediate catalyst for a breakout.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
GSBC vs JPM: Head-to-Head Comparison
This page compares Great Southern Bancorp, Inc. (GSBC) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.